Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2022 Jun 7;12:889996. doi: 10.3389/fonc.2022.889996

Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

Mark M Awad 1,*, Yvan Le Bruchec 2, Brian Lu 2, Jason Ye 3, Julie Ann Miller 2, Patrick H Lizotte 4, Megan E Cavanaugh 4, Amanda J Rode 4, Calin Dan Dumitru 2, Alexander Spira 5
PMCID: PMC9210944  PMID: 35747830

Angeliki Zarotiadou was not included in the Acknowledgments section in the published article. The corrected Acknowledgments section appears below.

“The authors thank the patients who participated in the study and their families. Additional thanks to Precision for Medicine, formerly ApoCell, for serum cytokine and blood immunophenotyping. Biostatistics assistance was provided by Angeliki Zarotiadou, MSc. Writing assistance was provided by Aaron Runkle, PhD, CMPP, of MediTech Media, Ltd, and funded by Bristol Myers Squibb. The authors presented these results in an abstract and poster at the 2019 ASCO Annual Meeting; May 31-June 4, 2019; Chicago, IL (40)”.

In the original article, the reference for NCCN Guidelines® for NSCLC V.1.2021 was incorrectly written in the in-text citation as “[Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCL V.1.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed (December 3, 2020). To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way]”.

It should be “[Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.1.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed (July 20, 2021). To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way]”.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES